Hemlibra 60 mg/0.4 ml (SC Injection)
60 mg vial: ৳ 147,160.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Emicizumab |
| Company | Roche bangladesh ltd |
| Also available as |
Indications
- Prevent or reduce the frequency of bleeding episodes in patients with hemophilia A
Pharmacology
- Mimics the function of coagulation factor VIII
- Binds to activated form of Factor IXa and Factor X
- Activates the coagulation cascade
- Restores blood coagulation process
- Reduces hemorrhagic episodes
Dosage & Administration
- Initial loading dose of 3 mg/kg once weekly for 4 weeks
- Maintenance dose of 1.5 mg/kg once weekly, or 3 mg/kg once every two weeks, or 6 mg/kg once every four weeks
Interaction
- Potential drug interaction with aPCC (Activated Prothrombin Complex Concentrate)
Side Effects
- Thrombotic Microangiopathy associated with Hemlibra and aPCC
- Thromboembolism associated with Hemlibra and aPCC
- Immunogenicity
Pregnancy & Lactation
- Limited data on use in pregnant women
- Unknown effects on fetal harm
- Consider potential benefit for mother vs. risk to fetus
- Unknown presence in human milk and effects on breastfed child
Precautions & Warnings
- Development of anti-Hemlibra antibodies
- Interference with coagulation laboratory tests
- Prompt assessment if loss of efficacy is observed
Storage Conditions
- Refrigeration at 2°C to 8°C
- Protection from light
- Avoid freezing and shaking
- Storage out of refrigeration for a limited time and temperature